iCellate Medical AB logo — Cancer profiling for precision oncology and early cancer det...

iCellate Medical AB

Cancer profiling for precision oncology and early cancer detection

Founded 2011 Sweden Sweden 8 employees

General Information

Company Name iCellate Medical AB
Founded Year 2011
Location Sweden Sweden
Employees 8
Social

BounceWatch is an independent company data service, not affiliated with iCellate Medical AB. To contact iCellate Medical AB, visit icellate.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does iCellate Medical AB compare?

A PDF of iCellate Medical AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting iCellate Medical AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About iCellate Medical AB

is a company dedicated to cancer profiling for precision oncology and early cancer detection. Established in 2011, iCellate specializes in developing and providing cancer profiling services through its innovative platforms, CellMate® and GeneMate®. CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® offers analysis for hereditary cancer and gBRCA testing. Despite the lack of specific information on industries and headquarters, iCellate's focus on utilizing advanced technologies for cancer diagnostics makes it an intriguing prospect for potential investors. As of now, there is no information available about the last investment and the investors involved. The potential of iCellate's innovative solutions in the burgeoning field of precision oncology could make it an attractive opportunity for venture capital firms seeking to invest in the healthcare and biotechnology sectors.

Business keywords: Cancer Profiling, Precision Oncology, Circulating Tumor Cells, Liquid Biopsy, Next Generation Sequencing, Comprehensive Biomarker Analysis, Early Cancer Detection, Hereditary Cancer Testing, gBRCA Testing, Solid Tumors, Diagnostic Services

No funding data available for iCellate Medical AB yet.

iCellate Medical AB Alternatives & Competitors

iCellate Medical AB vs
ANGLE
ANGLE United Kingdom

The leading experts in cancer cell capture and analysis from liquid biopsies

Post-IPO Equity
165 employees
Biotechnology, Health Care
iCellate Medical AB vs
SAGA Diagnostics
SAGA Diagnostics United States

Redefining the early detection of molecular residual disease (MRD).

Series A
97 employees
Biotechnology
iCellate Medical AB vs
Predicine
Predicine United States

Advancing precision medicine through next-generation liquid biopsy oncology platform

89 employees
Biotechnology, Health Care

FAQ About iCellate Medical AB

Cancer profiling for precision oncology and early cancer detection
iCellate Medical AB was founded in 2011.
iCellate Medical AB is headquartered in Sweden.
iCellate Medical AB has approximately 8 employees.
Top alternatives and competitors to iCellate Medical AB include ANGLE, SAGA Diagnostics, Predicine, RareCyte, Inc., Cellsway. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
iCellate Medical AB and ANGLE are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for iCellate Medical AB, https://bouncewatch.com/company/icellate-medical-ab, updated 8 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes